Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s

Fecha de publicación: 2 de octubre de 2026, 17:55

Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes.